MT2003-23:NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RI

MT2003-23：高 RI 中 NK 细胞输注的非清髓性半相合 HSCT

• 批准号: 7605991
• 负责人: DANIEL J WEISDORF
• 金额: $ 0.35万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605991
• 关键词: Cancer Relapse; Computer Retrieval of Information on Scientific Projects Database; Engraftment; Funding; Grant; Incidence; Infusion procedures; Institution; Natural Killer Cells; Patients; Research; Research Personnel; Resources; Risk; Safety; Source; Standards of Weights and Measures; Stem cells; Testing; Transplantation; Treatment Protocols; United States National Institutes of Health; day; graft vs host disease; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the effects of an infusion of natural killer (NK) cells given to patients receiving a reduced intensity pre-transplant regimen and stem cell trnsplant from a haploidentical related donor. Our hypothesis is that the addition of NK cells to this standard regimen will reduce the incidence of GVHD without compromising engraftment or leading to excess day +100 mortality. Additionally, the NK cell infusion may limit the risks of cancer relapse after transplant. We are also testing the safety of the NK cell infusion.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究旨在评估接受低强度移植前治疗方案和半相合相关供体干细胞移植的患者输注自然杀伤 (NK) 细胞的效果。 我们的假设是，在该标准方案中添加 NK 细胞将降低 GVHD 的发生率，而不会影响植入或导致 +100 天死亡率过高。 此外，NK 细胞输注可能会限制移植后癌症复发的风险。 我们还在测试 NK 细胞输注的安全性。